glp·helper
glphelper.com/mounjaro/california/san-marcos
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in San Marcos, CA

Verified Mounjaro providers in San Marcos, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
26
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
27 of 27 shown

Find a Mounjaro provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /mounjaro/california/{city}
§ 03Getting Mounjaro in San Marcos
27 providers · San Marcos, CA

How to get Mounjaro in San Marcos.

27 GLP-1 prescribers and 6 local resource types are on record for San Marcos, plus 3 nearby towns in the directory.

Prescribers in San Marcos
27 prescribers
27 GLP-1 prescribers in San Marcos, most listed as Family Medicine (12), Internal Medicine (10) and Family Medicine, Sports Medicine (2). Any California-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are Escondido (33 providers), Vista (28 providers) and Carlsbad (26 providers).
Around the prescription in San Marcos
6 listed nearby
21 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near San Marcos.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in San Marcos

San Marcos, California has a population of 94,833 people. The adult obesity rate in San Marcos is an age-adjusted estimate of 25.5%, 3.6 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 9.2% of adults in San Marcos. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 20.6% of adults in San Marcos.

of San Marcos adults have obesity
25.5%
diagnosed diabetes
9.2%
no regular physical activity
20.6%

Age-adjusted estimates for San Marcos, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshair shedding during weight loss
§ 05Support around Mounjaro in San Marcos
6 dietitians

The prescription is one part. Here is the rest, in San Marcos.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near San Marcos, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Misty Faulkner, RDN
RD
Registered dietitian
50100 Golsh Rd
Call 760-749-1410NPI 1609462092
Ellen Gowen, R.D
RD
Registered dietitian
150 Valpreda Rd
Call 760-471-2743NPI 1326366519
Stewart Guentner, Registered Dietitian
RD
Registered dietitian
495 Borden Cir
Call 760-435-2308NPI 1023387172
Carly Hill, R.D
RD
Registered dietitian
34800 Bob Wilson Dr
Call 619-532-8268NPI 1225385792
Torina Hommes, MS,RD
RD
Registered dietitian
3020 Childrens Way
Call 858-576-1700NPI 1912874090
Mackenzie Jones
RD
Registered dietitian
1274 Topanga Dr
Call 206-794-5183NPI 1235028986

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

LA Fitness
GYM
4.3 on Google · 727 reviews
125 N Twin Oaks Valley Rd
Website
LVLZ BOXING
GYM
5.0 on Google · 318 reviews
1342 E Mission Rd
Website
Planet Fitness
GYM
4.5 on Google · 306 reviews
641 S Rancho Santa Fe Rd
Website
F45 Training West San Marcos
GYM
5.0 on Google · 173 reviews
727 W San Marcos Blvd Unit 111
Website
Anytime Fitness
GYM
3.9 on Google · 76 reviews
1234 E Mission Rd
Website
MOA Fitness
GYM
4.9 on Google · 69 reviews
737 Windy Point Dr Ste H & I
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in California

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]